No headlines found.
No press releases found.
No news found.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
Geovax Labs trades on the NASDAQ stock market under the symbol GOVX.
As of July 8, 2026, GOVX stock price declined to $1.17 with 173,858 million shares trading.
GOVX has a beta of 1.23, meaning it tends to be more sensitive to market movements. GOVX has a correlation of 0.01 to the broad based SPY ETF.
GOVX has a market cap of $6.10 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GOVX traded as high as $279.50 and as low as $.96.
The top ETF exchange traded funds that GOVX belongs to (by Net Assets): VXF.
GOVX has underperformed the market in the last year with a price return of -90.7% while the SPY ETF gained +21.3%. GOVX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.3% and -9.3%, respectively, while the SPY returned +13.3% and +1.6%, respectively.
GOVX support price is $1.09 and resistance is $1.29 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GOVX shares will trade within this expected range on the day.
